glp 1 drugs and depression GLP-1 medications used to treat diabetes obesity may also help alleviate symptoms of anxiety and GLP-1 drugs linked to reduced
Description
Exposures Two cohorts were assembled, with the first composed of patients who started and continued on GLP-1 receptor agonists or DPP-4 inhibitors between 1 January 2007 and 31 December 2020 and the second composed of patients who started and continued on GLP-1 receptor agonists or SGLT-2 inhibitors between 1 January 1 2013 and 31 December 2020
Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF
New research suggests that around 10% of people carry genetic variations that help explain why.
GLP-1 medications are becoming one of the most important workplace health and benefits topics
